Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor

Journal of Medicinal Chemistry

Volumn 58, Issue 10, 2015, Pages 4266-4277

  Slavik, Roger ^a   Grether, Uwe ^b   Müller Herde, Adrienne ^a   Gobbi, Luca ^b   Fingerle, Jürgen ^b   Ullmer, Christoph ^b   Krämer, Stefanie D ^a   Schibli, Roger ^a,c   Mu, Linjing ^a,c   Ametamey, Simon M ^a  

^a ETH Zurich   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (METHOXYCARBONYL)PYRIDINE 1 OXIDE; 5 BROMO 6 (CYCLOPROPYLMETHOXY)PICOLINIC ACID; 5 CYCLOPENTYL 6 (CYCLOPROPYLMETHOXY)PICOLINIC ACID; 6 (CYCLOPROPYLMETHOXY) 5 (3 METHOXYAZETIDIN 1 YL) N [3 (METHYLCARBAMOYL)PENTAN 3 YL]PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) 5 (3 METHOXYAZETIDIN 1 YL) PICOLINIC ACID; 6 (CYCLOPROPYLMETHOXY) 5 (3,3 DIFLUOROAZETIDIN 1 YL) N [1 (5 (4 FLUOROPHENYL) 1,3,4 OXADIOZOL 2 YL) 2 METHYLPROPAN 2 YL]PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) 5 (3,3 DIFLUOROAZETIDIN 1 YL) N [2 (5 (PYRIDIN 3 YL) 1,3,4 OXADIOZOL 2 YL)PROPAN 2 YL]PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) 5 (3,3 DIFLUOROAZETIDIN 1 YL) N [2 (5 PHENYL 1,3,4 OXADIAZOL 2 YL)PROPAN 2 YL]PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) 5 (3,3 DIFLUOROAZETIDIN 1 YL) N [3 ((2 FLUOROETHYL)CARBAMOYL)PENTAN 3 YL]PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) 5 (3,3 DIFLUOROAZETIDIN 1 YL) N [3 (METHYLCARBAMOYL)PENTAN 3 YL]PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) 5 (3,3 DIFLUOROAZETIDIN 1 YL)PICOLINIC ACID; 6 (CYCLOPROPYLMETHOXY) N [(1 HYDROXYCYCLOHEXYL)METHYL] 5 (3 METHOXYAZETIDIN 1 YL)PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) N [1 (5 (4 FLUOROPHENYL) 1,3,4 OXADIAZOL 2 YL) 2 METHYLPROPAN 2 YL] 5 (3 METHOXYAZETIDIN 1 YL)PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) N [3 ((2 FLUOROETHYL)CARBAMOYL)PENTAN 3 YL] 5 (3 METHOXYAZETIDIN 1 YL)PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) N [3 ((3 FLUOROPROPYL)CARBAMOYL)PENTAN 3 YL] 5 (3 METHOXYAZETIDIN 1 YL)PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) N [3 (1 HYDROXY 2 METHYLPROPAN 2 YL)ISOXAZOL 5 YL] 5 (3 METHOXYAZETIDIN 1 YL)PICOLINAMIDE; 6 (CYCLOPROPYLMETHOXY) N [3 (3 FLUOROAZETIDIN 1 CARBONYL)PENTAN 3 YL] 5 (3 METHOXYAZETIDIN 1 YL)PICOLINAMIDE; CANNABINOID 2 RECEPTOR; CARBON 11; ETHYL 2 [6 (CYCLOPROPYLMETHOXY) 5 (3 METHOXYAZETIDIN 1 YL)PICOLINAMIDO] 2 ETHYLBUTANOATE; LIPOPOLYSACCHARIDE; METHYL 5 BROMO 6 (CYCLOPROPYLMETHOXY)PICOLINIC ACID; METHYL 5 BROMO 6 CHLOROPICOLINATE; METHYL 6 (CYCLOPROPYLMETHOXY) 5 (3,3 DIFLUOROAZETIDIN 1 YL)PICOLINIC ACID; N [1 (5 CYCLOBUTYL 1,3,4 OXADIAZOL 2 YL) 2 METHYLPROPAN 2 YL] 6 (CYCLOPROPYLMETHOXY) 5 (3 METHOXYAZETIDIN 1 YL)PICOLINAMIDE; N [2 (5 CYCLOPROPYL 1,3,4 OXADIAZOL 2 YL)PROPAN 2 YL] 6 (CYCLOPROPYLMETHOXY) 5 (3,3 DIFLUOROAZETIDIN 1 YL)PICOLINAMIDE; N [3 (2 AMINO 2 OXOETHYL)OXETAN 3 YL] 6 (CYCLOPROPYLMETHOXY) 5 (3 METHOXYAZETIDIN 1 YL)PICOLINAMIDE; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; AZETIDINE DERIVATIVE; CANNABINOID 1 RECEPTOR; CNR2 PROTEIN, HUMAN; CONTRAST MEDIUM; PICOLINIC ACID DERIVATIVE; RSR056 AZETIDINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPOPHILICITY; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; SUZUKI REACTION; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; DIAGNOSTIC USE; DRUG DEVELOPMENT; DRUG SCREENING; DRUG STABILITY; GENETICS; INBRED MOUSE STRAIN; METABOLISM; PROCEDURES; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; AZETIDINES; CHO CELLS; CONTRAST MEDIA; CRICETULUS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HUMANS; MALE; MICE, INBRED STRAINS; PICOLINIC ACIDS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TISSUE DISTRIBUTION;

EID: 84930673329     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00283     Document Type: Article

References (34)

1. Pertwee, R. G.; Howlett, A. C.; Abood, M. E.; Alexander, S. P.; Di Marzo, V.; Elphick, M. R.; Greasley, P. J.; Hansen, H. S.; Kunos, G.; Mackie, K.; Mechoulam, R.; Ross, R. A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2) Pharmacol. Rev. 2010, 62, 588-631
2. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990, 346, 561-564
3. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365, 61-65
4. Johns, D. G.; Behm, D. J.; Walker, D. J.; Ao, Z.; Shapland, E. M.; Daniels, D. A.; Riddick, M.; Dowell, S.; Staton, P. C.; Green, P.; Shabon, U.; Bao, W.; Aiyar, N.; Yue, T. L.; Brown, A. J.; Morrison, A. D.; Douglas, S. A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects Br. J. Pharmacol. 2007, 152, 825-831
5. Overton, H. A.; Fyfe, M. C.; Reynet, C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity Br. J. Pharmacol. 2008, 153 (Suppl. 1) 76-81
6. McHugh, D.; Hu, S. S.; Rimmerman, N.; Juknat, A.; Vogel, Z.; Walker, J. M.; Bradshaw, H. B. N -Arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor BMC Neurosci. 2010, 11, 44
7. Szallasi, A.; Di Marzo, V. New perspectives on enigmatic vanilloid receptors Trends Neurosci. 2000, 23, 491-497
8. Pertwee, R. G. Pharmacology of cannabinoid CB1 and CB2 receptors Pharmacol. Ther. 1997, 74, 129-180
9. Miller, A. M.; Stella, N. CB2 receptor-mediated migration of immune cells: It can go either way Br. J. Pharmacol. 2008, 153, 299-308
10. Van Sickle, M. D.; Duncan, M.; Kingsley, P. J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J. S.; Marnett, L. J.; Di Marzo, V.; Pittman, Q. J.; Patel, K. D.; Sharkey, K. A. Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 2005, 310, 329-332
11. Ashton, J. C.; Friberg, D.; Darlington, C. L.; Smith, P. F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study Neurosci. Lett. 2006, 396, 113-116
12. Brusco, A.; Tagliaferro, P.; Saez, T.; Onaivi, E. S. Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus Synapse 2008, 62, 944-949
13. Benito, C.; Tolon, R. M.; Pazos, M. R.; Nunez, E.; Castillo, A. I.; Romero, J. Cannabinoid CB2 receptors in human brain inflammation Br. J. Pharmacol. 2008, 153, 277-285
14. Onaivi, E. S. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications Int. Rev. Neurobiol. 2009, 88, 335-369
15. Shoemaker, J. L.; Seely, K. A.; Reed, R. L.; Crow, J. P.; Prather, P. L. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset J. Neurochem. 2007, 101, 87-98
16. Yiangou, Y.; Facer, P.; Durrenberger, P.; Chessell, I. P.; Naylor, A.; Bountra, C.; Banati, R. R.; Anand, P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord BMC Neurol. 2006, 6, 12
17. Evens, N.; Muccioli, G. G.; Houbrechts, N.; Lambert, D. M.; Verbruggen, A. M.; Van Laere, K.; Bormans, G. M. Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging Nucl. Med. Biol. 2009, 36, 455-465
18. Slavik, R.; Bieri, D.; Cermak, S.; Muller, A.; Kramer, S. D.; Weber, M.; Schibli, R.; Ametamey, S. M.; Mu, L. Development and evaluation of novel PET tracers for imaging cannabinoid receptor type 2 in brain Chimia (Aarau) 2014, 68, 208-210
19. Horti, A. G.; Gao, Y.; Ravert, H. T.; Finley, P.; Valentine, H.; Wong, D. F.; Endres, C. J.; Savonenko, A. V.; Dannals, R. F. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2) Bioorg. Med. Chem. 2010, 18, 5202-5207
20. Evens, N.; Vandeputte, C.; Muccioli, G. G.; Lambert, D. M.; Baekelandt, V.; Verbruggen, A. M.; Debyser, Z.; Van Laere, K.; Bormans, G. M. Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging Bioorg. Med. Chem. 2011, 19, 4499-4505
21. Vandeputte, C.; Evens, N.; Toelen, J.; Deroose, C. M.; Bosier, B.; Ibrahimi, A.; Van der Perren, A.; Gijsbers, R.; Janssen, P.; Lambert, D. M.; Verbruggen, A.; Debyser, Z.; Bormans, G.; Baekelandt, V.; Van Laere, K. A PET brain reporter gene system based on type 2 cannabinoid receptors J. Nucl. Med. 2011, 52, 1102-1109
22. Ruhl, T.; Deuther-Conrad, W.; Fischer, S.; Gunther, R.; Hennig, L.; Krautscheid, H.; Brust, P. Cannabinoid receptor type 2 (CB2)-selective N -aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation Org. Med. Chem. Lett. 2012, 2, 32
23. Hortala, L.; Arnaud, J.; Roux, P.; Oustric, D.; Boulu, L.; Oury-Donat, F.; Avenet, P.; Rooney, T.; Alagille, D.; Barret, O.; Tamagnan, G.; Barth, F. Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor Bioorg. Med. Chem. Lett. 2014, 24, 283-287
24. Evens, N.; Bosier, B.; Lavey, B. J.; Kozlowski, J. A.; Vermaelen, P.; Baudemprez, L.; Busson, R.; Lambert, D. M.; Van Laere, K.; Verbruggen, A. M.; Bormans, G. M. Labelling and biological evaluation of [(11)C]methoxy-Sch225336: a radioligand for the cannabinoid-type 2 receptor Nucl. Med. Biol. 2008, 35, 793-800
25. Ullmer, C.; Zoffmann, S.; Bohrmann, B.; Matile, H.; Lindemann, L.; Flor, P.; Malherbe, P. Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7 Br. J. Pharmacol. 2012, 167, 1448-1466
26. Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs NeuroRx 2005, 2, 541-553
27. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur. J. Biochem. 1995, 232, 54-61
28. Gallant, M.; Dufresne, C.; Gareau, Y.; Guay, D.; Leblanc, Y.; Prasit, P.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Metters, K. M.; Labelle, M. New class of potent ligands for the human peripheral cannabinoid receptor Bioorg. Med. Chem. Lett. 1996, 6, 2263-2268
29. Qin, L.; Wu, X.; Block, M. L.; Liu, Y.; Breese, G. R.; Hong, J. S.; Knapp, D. J.; Crews, F. T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration Glia 2007, 55, 453-462
30. Slavik, R.; Herde, A. M.; Bieri, D.; Weber, M.; Schibli, R.; Krämer, S. D.; Ametamey, S. M.; Mu, L. Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor Eur. J. Med. Chem. 2015, 95, 554-564
31. Bissantz, C.; Grether, U.; Hebeisen, P.; Kimbara, A.; Liu, Q.; Nettekoven, M.; Prunotto, M.; Roever, S.; Rogers-Evans, M.; Schulz-Gasch, T.; Ullmer, C.; Wang, Z.; Yang, W. Pyridine-2-amides useful as CB2 agonists. Patent WO2012168350 A1, 2012.
32. Zhou, T.; Zhao, L.; Zhan, R.; He, Q.; Tong, Y.; Tian, X.; Wang, H.; Zhang, T.; Fu, Y.; Sun, Y.; Xu, F.; Guo, X.; Fan, D.; Han, H.; Chui, D. Blood-brain barrier dysfunction in mice induced by lipopolysaccharide is attenuated by dapsone Biochem. Biophys. Res. Commun. 2014, 453, 419-424
33. Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulet, J. M.; Gottshall, S. L.; Mark, L.; Pearson, M. S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Elsemore, D. A.; Toth, M.; Koetzner, L.; Whiteside, G. T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy Neuropharmacology 2005, 48, 658-672
34. Wilson, A. A.; Jin, L.; Garcia, A.; DaSilva, J. N.; Houle, S. An admonition when measuring the lipophilicity of radiotracers using counting techniques Appl. Radiat. Isot. 2001, 54, 203-208